Expert Interview
A Second Look: Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Ticker(s): VRTX, BLUE, CRSPInstitution: McKibbin Group
- Principal and Founder of the McKibbin Group.
- 20 years of experience consulting to large public entities, employers and foundations on a variety of health care and public policy issues.
- Former Special Advocate for Prescription Drugs for the state of Illinois, responsible for overseeing the state’s $1.8 billion annual prescription drug spending and state programs including Medicaid, Illinois Cares Rx (a Medicare Part D wraparound program), Illinois Rx Buying Club, state employee/retiree programs and prescription drugs dispensed at mental health facilities and correctional facilities.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
